Trodelvy Powder, For Solution
Product Images NDC 55135-132

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Trodelvy (NDC 55135-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Trodelvy 01

Chemical structure diagram illustrating the antibody-drug conjugate of Sacituzumab Govitecan (TRODELVY). It shows the hRS7 IgGk antibody linked via a specific chemical linker to the SN-38 payload molecule, indicating approximately 7.6 SN-38 molecules per antibody.*

FDA Label Image

Trodelvy 02

A Kaplan-Meier survival curve comparing the probability of progression-free survival (PFS) over time in months between patients treated with Trodelvy and those treated with chemotherapy. The graph includes censored data points and a table indicating the number of patients at risk in each group at various time intervals.*

FDA Label Image

Trodelvy 03

A Kaplan-Meier survival curve showing the probability of overall survival (OS) over 24 months comparing Trodelvy and chemotherapy. The y-axis represents the probability of OS (%) and the x-axis represents time in months. The plot includes a table listing the number of patients at risk at various time points for both Trodelvy and chemotherapy groups.*

FDA Label Image

Trodelvy 04

Label for TRODELVY 180 mg per vial powder for solution injection, sacituzumab govitecan-hziy, for intravenous infusion only. It is a single-dose vial labeled as a hazardous drug. The label includes storage instructions (2°C to 8°C), reconstitution directions with 20 mL of 0.9% sodium chloride injection, and manufacturing information, showing Gilead Sciences, Inc. as the manufacturer.*

FDA Label Image

Trodelvy 05

Packaging label for TRODELVY sacituzumab govitecan-hziy 180 mg powder for solution for injection. The label indicates it is for intravenous infusion only, a single-dose vial, and a hazardous drug. It includes the labeler Gilead Sciences, Inc., dosage instructions, inactive ingredients, storage conditions, and a barcode. The NDC is 55135-132-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.